GlassScriptPhysician profile
Cecil B Breetzke
NPI 1629142955
$8,730.21
in general payments reported to CMS, 2019-2025
51 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $133 · 2021: $983 · 2022: $1,555 · 2023: $1,438 · 2024: $1,741 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008 · Entertainment: $13.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,007.55 |
| Entertainment | $13.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,816.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $824.93 | 2019-2025 | |
| Abbvie INC. | $764.76 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Abbott Laboratories | $462.28 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $450.11 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $405.81 | 2019-2022 | |
| Lilly USA, LLC | $379.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $354.63 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $335.23 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $239.19 | 2020-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.85 | 2019-2022 | |
| Dexcom, INC. | $184.15 | 2021-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $180.00 | 2021-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $178.15 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.31 | 2022-2025 | Xifaxan, Trulance |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $164.11 | 2022 | |
| Medtronic, INC. | $134.03 | 2023-2025 | Inceptiv, Intellis Adaptivestim, Minimed 780g |
| Biohaven Pharmaceuticals, INC. | $121.71 | 2021 | |
| Xeris Pharmaceuticals, INC. | $95.59 | 2023-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $82.30 | 2019-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $80.74 | 2025 | Rexulti |
| Exact Sciences Corporation | $77.81 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $72.15 | 2020-2023 | Belsomra, Steglatro |
| Lundbeck LLC | $71.68 | 2023-2025 | Vyepti, Rexulti |
| Glaxosmithkline, LLC. | $70.79 | 2020-2024 | Shingrix, Boostrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $69.97 | 2021-2022 | |
| Smith+Nephew, INC. | $63.12 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $53.09 | 2024 | Fanapt |
| Antares Pharma, INC. | $52.53 | 2019-2024 | Xyosted |
| Shield Therapeutics INC | $46.47 | 2023-2024 | Accrufer |
| Nevro Corp. | $45.07 | 2023 | Senza |
| Corcept Therapeutics | $42.90 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.46 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $39.29 | 2025 | Inspire |
| Boston Scientific Corporation | $39.05 | 2022-2024 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $31.24 | 2023 | Quviviq |
| Insulet Corporation | $25.67 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $25.11 | 2022 | |
| Sumitomo Pharma America, INC. | $22.85 | 2025 | Gemtesa |
| Globus Medical, INC. | $18.60 | 2025 | Senza |
| Hartmann USA, INC. | $18.19 | 2021 | |
| Kci USA, INC. | $17.75 | 2021 | |
| Radius Health, INC. | $17.35 | 2019 | |
| Aytu Biopharma, INC. | $16.96 | 2019 | |
| Allergan, INC. | $15.08 | 2019 | |
| Esperion Therapeutics, INC. | $14.53 | 2021 | |
| Shire North American Group INC | $14.12 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.96 | 2024 | |
| Optos, INC. | $13.91 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kyowa Kirin, INC. | $13.80 | 2024 | Crysvita |
| Kowa Pharmaceuticals America, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecil Breetzke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.